Navigation Links
NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
Date:10/22/2008

Marketing Application Submitted on Schedule

SAN MATEO, Calif., Oct. 22 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that it has submitted a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for approval to market its investigational product candidate, NGX-4010, for the management of pain due to postherpetic neuralgia (PHN). NeurogesX anticipates that the application, which is subject to acceptance by the FDA, will be subject to a standard review with a Prescription Drug User Fee Act (PDUFA) date in the second half of 2009.

NGX-4010, the Company's lead product candidate, is a dermal high-concentration capsaicin patch. The NDA submission is supported by two pivotal studies of NGX-4010 in patients with PHN. The results of these clinical trials show a statistically significant reduction in pain from baseline for up to 12 weeks after a single 60-minute application of the dermal patch. In these studies, NGX-4010 could be administered either as a monotherapy or in combination with other systemic neuropathic pain medications. The most common adverse reactions associated with NGX-4010 were redness, pain, and itching at the application site during and shortly after application. The NDA clinical package includes data on over 2300 patients with neuropathic pain.

Anthony DiTonno, President and CEO, commented, "Our top priority is to secure marketing approval of NGX-4010 in both the United States and Europe. With the submission of our NDA and the ongoing review of our Marketing Authorization Application in the European Union, from which we anticipate a decision in the first ha
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeurogesX Responds to EMEAs Day 120 Questions
2. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
3. NeurogesX Reports Second Quarter 2008 Results
4. NeurogesX to Report Second Quarter 2008 Financial Results
5. NeurogesX Opens Investigational New Drug Application for Capsaicin Liquid Formulation NGX-1998
6. NeurogesX to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
7. NeurogesX Reports First Quarter 2008 Results
8. NeurogesX to Report First Quarter 2008 Financial Results
9. NeurogesX to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference
10. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
11. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... (PRWEB) September 19, 2014 ... its potential to revolutionize the world has attracted ... corporations and small start-ups. The early years of ... projects largely due to the high risks involved, ... budgets earmarked for this evolving technology have been ...
(Date:9/19/2014)... 19, 2014 Biotech companies make ... emerging drug systems and advanced Laboratory Instrumentation. Companies in ... (NYSE: BDX ), Thermo Fisher Scientific Inc. ... RGDO ), Sangamo Biosciences Inc. (NASDAQ: ... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the ...
(Date:9/19/2014)... DIEGO , Sept. 19, 2014 Pfenex ... in the development of high-value and difficult to manufacture ... be presenting at the 21 st Annual NewsMakers ... York . Bertrand Liang , chief executive ... company,s development programs and business strategy on Friday, September ...
(Date:9/19/2014)... September 19, 2014 Barnhardt Manufacturing ... Label for its Organic Cotton . The USDA ... of renewable biobased ingredients meets or exceeds levels set ... composed in whole or in significant part of agricultural, ... allow our Organic cotton to be immediately identified as ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Pfenex to Present at Upcoming Industry Conference on September 26 2Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2
... ATLANTA, Oct. 12, 2011 CorMatrix Cardiovascular, Inc., ... delivering unique extracellular matrix (ECM) biomaterial devices that ... cardio-vascular tissue, announced today that the U.S. Food ... 510(k) clearance to market its CorMatrix® ECM® for ...
... 2011 Reportlinker.com announces that a new ... catalogue: Industrial Biotechnology ... http://www.reportlinker.com/p0655292/Industrial-Biotechnology-China-News-1109---Annual-Subscription.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Renewable_energy ... of Biotechnology Industry to be published in ...
... - Two pivotal trials initiated for treatment of iron ... - Shield Therapeutics (Shield), the independent specialty ... late-stage, mineral-derived hospital pharmaceuticals which address areas of high ... have been treated in the two Phase 3 clinical ...
Cached Biology Technology:CorMatrix Receives Carotid Artery Repair Indication for its CorMatrix® ECM® 2CorMatrix Receives Carotid Artery Repair Indication for its CorMatrix® ECM® 3Industrial Biotechnology China News 1109 - Annual Subscription 2Industrial Biotechnology China News 1109 - Annual Subscription 3Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10 2Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10 3
(Date:9/18/2014)... algal forests in the eastern Mediterranean Sea pose a ... distribution continues to expand as the climate warms, a ... of researchers led by Dr Adriana Vergs of UNSW ... for Advanced Studies in Spain, is published in the ... surveyed more than 1000 kilometres of coastline in Turkey ...
(Date:9/18/2014)... the ideal animal in which to study the genes ... into tens of thousands of freshwater streams and lakes ... adapt to the new environment. , Breeding studies between ... up one of the genes that controls tooth number, ... regulation in a freshwater population is associated with a ...
(Date:9/17/2014)... accessible and affordable health care to reproductive technologies, ... on the ability of people to identify key ... and respectfully, and find the most defensible ways ... to support these societal conversations?, The Hastings Center ... Bioethical Issues have teamed up to publish a ...
Breaking Biology News(10 mins):Tropical fish a threat to Mediterranean Sea ecosystems 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Why bioethics literacy matters 2Why bioethics literacy matters 3
... a huge portion of real estate in western North ... and fossils very different from those in adjacent terranes. ... tectonic styles, metamorphism, and volcanic origins, much like the ... new Geological Society of America Special Paper brings together ...
... Washington, DCMay 28, 2008The 2008 American Society for ... Diagnostic Immunology is presented to Steven A. Rosenberg, ... Surgery, Uniformed Services University of the Health Sciences, ... of Medicine and Health Sciences. Sponsored by Abbott ...
... for Microbiology (ASM) Merck Irving S. Sigal Memorial Award ... Genetics and Microbiology, University of Texas at Austin. Sponsored ... Memorial Award is presented in memory of Irving S. ... therapies to treat HIV/AIDS, to recognize excellence in basic ...
Cached Biology News:American Society for Microbiology honors Steven A. Rosenberg 2
... is a new-generation siRNA transfection reagent that ... 1 nM siRNA in a wide variety ... cell viability. Using low siRNA concentrations avoids ... when transfecting siRNA at higher concentrations, thereby ...
... Cell and Tissue Staining Kits are intended ... range of histological and cytological specimens. These ... antibodies manufactured by either R&D Systems or ... on the formation of the Avidin-Biotin Complex ...
... stranded RNA (dsRNA) has been shown to ... of organisms as well as insect cells ... inhibition of protein expression by utilizing sequence-specific, ... (mRNA). Attempts to induce RNA interference using ...
... jetSI-ENDO is an easy-to-use siRNA transfection reagent ... endogenous genes in a variety of cell ... with an optimized, straightforward protocol. High levels ... obtained following transfection of 20 to 100 ...
Biology Products: